Seroatlas · Human Serome Atlas

TGM2

Protein-glutamine gamma-glutamyltransferase 2

Also known as: TGC, TGM2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P21980
Gene
TGM2
Ensembl
ENSG00000198959
Chromosome
20
Canonical length
687 aa
Protein class
Disease related genes, Enzymes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins
Subcellular location
Plasma membrane,Cytosol
Secretome location
Secreted to extracellular matrix
Quaternary structure
Homooligomer

OverviewNCBI Gene

Transglutaminases are enzymes that catalyze the crosslinking of proteins by epsilon-gamma glutamyl lysine isopeptide bonds. While the primary structure of transglutaminases is not conserved, they all have the same amino acid sequence at their active sites and their activity is calcium-dependent. The protein encoded by this gene acts as a monomer, is induced by retinoic acid, and appears to be involved in apoptosis. Finally, the encoded protein is the autoantigen implicated in celiac disease. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

687 residues, UniProt reviewed canonical sequence.

>P21980|TGM2
     1  MAEELVLERC DLELETNGRD HHTADLCREK LVVRRGQPFW LTLHFEGRNY EASVDSLTFS
    61  VVTGPAPSQE AGTKARFPLR DAVEEGDWTA TVVDQQDCTL SLQLTTPANA PIGLYRLSLE
   121  ASTGYQGSSF VLGHFILLFN AWCPADAVYL DSEEERQEYV LTQQGFIYQG SAKFIKNIPW
   181  NFGQFEDGIL DICLILLDVN PKFLKNAGRD CSRRSSPVYV GRVVSGMVNC NDDQGVLLGR
   241  WDNNYGDGVS PMSWIGSVDI LRRWKNHGCQ RVKYGQCWVF AAVACTVLRC LGIPTRVVTN
   301  YNSAHDQNSN LLIEYFRNEF GEIQGDKSEM IWNFHCWVES WMTRPDLQPG YEGWQALDPT
   361  PQEKSEGTYC CGPVPVRAIK EGDLSTKYDA PFVFAEVNAD VVDWIQQDDG SVHKSINRSL
   421  IVGLKISTKS VGRDEREDIT HTYKYPEGSS EEREAFTRAN HLNKLAEKEE TGMAMRIRVG
   481  QSMNMGSDFD VFAHITNNTA EEYVCRLLLC ARTVSYNGIL GPECGTKYLL NLNLEPFSEK
   541  SVPLCILYEK YRDCLTESNL IKVRALLVEP VINSYLLAER DLYLENPEIK IRILGEPKQK
   601  RKLVAEVSLQ NPLPVALEGC TFTVEGAGLT EEQKTVEIPD PVEAGEEVKV RMDLLPLHMG
   661  LHKLVVNFES DKLKAVKGFR NVIIGPA

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TGM2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.22
Highest tissue expression
776 nTPM

Expression across tissuesHPA

Tissue

  • blood vessel: 776 nTPM
  • cervix: 413 nTPM
  • heart muscle: 391 nTPM
  • lung: 295 nTPM
  • endometrium: 264 nTPM
  • liver: 246 nTPM

Single-cell type

  • decidual stromal cells: 1,215 nCPM
  • epididymal efferent duct absorptive cells: 825 nCPM
  • syncytiotrophoblasts: 454 nCPM
  • cytotrophoblasts: 400 nCPM
  • endometrial stromal cells: 343 nCPM
  • lymphatic endothelial cells: 299 nCPM

Immune cell

  • intermediate monocyte: 0.6 nTPM
  • myeloid DC: 0.6 nTPM
  • memory B-cell: 0.4 nTPM
  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM

Brain region

  • choroid plexus: 78 nTPM
  • thalamus: 34 nTPM
  • pons: 25 nTPM
  • medulla oblongata: 24 nTPM
  • spinal cord: 21 nTPM
  • white matter: 21 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TGM2.

Disease | ImmuneIEDB

Conditions an epitope on TGM2 was assayed in.

Disease | AutoantibodyPubMed

Conditions in which antibodies against TGM2 are reported. Each links to that disease's full target list.

Showing 20 of 43 — disease pages carrying at least 10 antigens.

ReferencesPubMed · IEDB

Publications for TGM2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

952 publications

Show 20 more of 952 total

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.19
gnomAD pLI
0
gnomAD missense Z
0.54
DepMap mean gene effect
0.11
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TGM2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TGM2 as an antibody target. Whether an autoantibody or antibody against TGM2 could matter depends on whether native TGM2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TGM2 is annotated at the cell surface, where native TGM2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Source-annotated serology context

The source annotations explicitly mention antibody, autoantibody, autoantigen, or autoimmune context. This is biological context, not study-specific reactivity.

  • Finally, the encoded protein is the autoantigen implicated in celiac disease.

Canonical record: https://seroatlas.com/gene/TGM2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...